These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 18472966)

  • 1. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors.
    Kuwai T; Nakamura T; Sasaki T; Kim SJ; Fan D; Villares GJ; Zigler M; Wang H; Bar-Eli M; Kerbel RS; Fidler IJ
    Neoplasia; 2008 May; 10(5):489-500. PubMed ID: 18472966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation on tumor-associated endothelial cells leads to treatment of orthotopic human colon cancer in nude mice.
    Sasaki T; Kitadai Y; Nakamura T; Kim JS; Tsan RZ; Kuwai T; Langley RR; Fan D; Kim SJ; Fidler IJ
    Neoplasia; 2007 Dec; 9(12):1066-77. PubMed ID: 18084614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model.
    Yokoi K; Thaker PH; Yazici S; Rebhun RR; Nam DH; He J; Kim SJ; Abbruzzese JL; Hamilton SR; Fidler IJ
    Cancer Res; 2005 May; 65(9):3716-25. PubMed ID: 15867367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
    Solorzano CC; Baker CH; Tsan R; Traxler P; Cohen P; Buchdunger E; Killion JJ; Fidler IJ
    Clin Cancer Res; 2001 Aug; 7(8):2563-72. PubMed ID: 11489840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
    Kedar D; Baker CH; Killion JJ; Dinney CP; Fidler IJ
    Clin Cancer Res; 2002 Nov; 8(11):3592-600. PubMed ID: 12429651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
    Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
    Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
    J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
    Bruns CJ; Solorzano CC; Harbison MT; Ozawa S; Tsan R; Fan D; Abbruzzese J; Traxler P; Buchdunger E; Radinsky R; Fidler IJ
    Cancer Res; 2000 Jun; 60(11):2926-35. PubMed ID: 10850439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
    Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells in human renal cell carcinoma is a primary target for therapy by tyrosine kinase inhibitors.
    Baker CH; Pino MS; Fidler IJ
    Neoplasia; 2006 Jun; 8(6):470-6. PubMed ID: 16820093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR is dispensable for c-Met-mediated proliferation and survival activities in mouse adult liver oval cells.
    Martínez-Palacián A; Del Castillo G; Herrera B; Fernández M; Roncero C; Fabregat I; Sánchez A
    Cell Signal; 2012 Feb; 24(2):505-513. PubMed ID: 22001397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.
    Lyros O; Mueller A; Heidel F; Schimanski CC; Gockel I; Galle PR; Lang H; Moehler M
    Int J Cancer; 2010 Sep; 127(5):1197-208. PubMed ID: 20039326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells.
    Shimizu M; Deguchi A; Lim JT; Moriwaki H; Kopelovich L; Weinstein IB
    Clin Cancer Res; 2005 Apr; 11(7):2735-46. PubMed ID: 15814656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.
    Thomson S; Petti F; Sujka-Kwok I; Epstein D; Haley JD
    Clin Exp Metastasis; 2008; 25(8):843-54. PubMed ID: 18696232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy.
    Kuwai T; Nakamura T; Sasaki T; Kitadai Y; Kim JS; Langley RR; Fan D; Wang X; Do KA; Kim SJ; Fidler IJ
    Clin Exp Metastasis; 2008; 25(4):477-89. PubMed ID: 18324358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
    Amin DN; Bielenberg DR; Lifshits E; Heymach JV; Klagsbrun M
    Microvasc Res; 2008 May; 76(1):15-22. PubMed ID: 18440031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.